Converting borderline-resectable, locally-advanced esophageal carcinoma to resectability with neoadjuvant chemoradiotherapy

Autor:	Joel S. Greenberger, Weijing Sun, Dwight E. Heron, Zachary D. Horne, James D. Luketich, Michael K. Gibson, Brian J Karlovits, Arjun Pennathur
Rok vydání:	2017
Předmět:	Cancer Research medicine.medical_specialty Proportional hazards model business.industry medicine.medical_treatment Esophageal cancer medicine.disease Carboplatin Surgery Regimen chemistry.chemical_compound Oncology Paclitaxel chemistry Esophagectomy Cohort medicine Carcinoma business
Zdroj:	Journal of Clinical Oncology. 35:160-160
ISSN:	1527-7755 0732-183X
Popis:	160 Background: Treatment of T3-4/N+ esophageal cancer is challenging. Outcomes are suboptimal and patterns of care are not well defined for borderline-resectable esophageal cancer (BREC). We present our institutional experience using preoperative chemoradiotherapy (CRT) in the management of BREC. Methods: We identified 67 patients with T3-4/N+ BREC who were treated with concurrent CRT between 2009 and 2014. Survival was calculated with Kaplan-Meier curves and cohort comparisons were made with log-rank test and Cox regression. Results: We treated 67 patients (81% males, median age 61 years, and KPS of 80), primarily with T3N2 disease. Median follow-up was 16 months. The most common CRT regimen was 58.8Gy in 28 fractions with carboplatin and paclitaxel. Median survival was 16.5 months. Forty two (62.7%) patients underwent minimally invasive Ivor-Lewis esophagectomy within 100 days of CRT. Resected patients had a median survival of 30.6 vs. 6.4 months without surgery (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::9e9290a06a34f263e951f506eacf018c https://doi.org/10.1200/jco.2017.35.4_suppl.160 Zobrazit plný text záznamu